Benzinga

Benzinga

Benzinga

martes, agosto 25

Halozyme Therapeutics Inc

HALONASDAQ
Trade with Public
Trade with Public
$109.04
0.400.37%
Últ. Act.: Aug 25, 9:36 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Halozyme Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Halozyme Therapeutics (HALO).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

2S.Buy
5Buy
3Hold
Consensus RatingBuy# Analysts10Avg. Consensus PT$83Upside to Avg. PT-24.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 7, 2026Leerink PartnersDavid RisingerUpgradeMarket Perform→Outperform$83→$110
Aug 7, 2026TD CowenBrendan SmithPT RaiseBuy$96→$105
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Raises Price Target to $95

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weight and raises the price target from $75 to $95.
Benzinga Newsdesk

Atlassian To Rally More Than 63%? Here Are 10 Top Analyst Forecasts For Friday

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes including upgrades & downgrades on Benzinga analyst ratings page.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $115

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $95 to $115.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved